Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis

CONCLUSIONS: Treatment of stage IIIa lung cancer requires the input of a multidisciplinary team who must consider cost, quality of life, and overall survival. As new treatments are developed, further analyses should be performed to determine optimal therapy.PMID:38505073 | PMC:PMC10944766 | DOI:10.21037/jtd-23-1538

Source: Journal of Thoracic Disease - March 20, 2024 Category: Respiratory Medicine Authors: Brian Mitzman Thomas K Varghese Wallace L Akerley Richard E Nelson Source Type: research